Price
Financials
Consolidated, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3 | 2 | 2 | 1 | 3 | 2 | 1 | 2 | 1 | 3 | 2 | 4 |
| Expenses | 27 | 49 | 33 | 32 | 55 | 41 | 45 | 53 | 81 | 106 | 52 | 136 |
| Operating Profit | -24 | -46 | -30 | -31 | -52 | -39 | -44 | -51 | -80 | -103 | -51 | -132 |
| OPM % | -768% | -1,885% | -1,267% | -3,024% | -2,032% | -2,435% | -2,981% | -2,714% | -8,671% | -3,678% | -3,331% | -3,711% |
| Other Income | 13 | 6 | 4 | 4 | 4 | 2 | 1 | 1 | 4 | 3 | 7 | 8 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 2 | 2 |
| Profit before tax | -13 | -42 | -28 | -28 | -50 | -39 | -44 | -52 | -77 | -102 | -46 | -128 |
| Tax % | 0% | 0% | -4% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -13 | -42 | -27 | -28 | -50 | -39 | -44 | -52 | -77 | -102 | -46 | -128 |
| EPS in Rs | -0.58 | -1.91 | -1.22 | -1.29 | -2.28 | -1.79 | -2.01 | -2.36 | -3.40 | -4.48 | -1.73 | -4.83 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 499 | 543 | 625 | 286 | 13 | 13 | 12 | 14 | 12 | 7 | 7 | 9 |
| Expenses | 398 | 414 | 427 | 300 | 128 | 93 | 134 | 139 | 140 | 172 | 291 | 375 |
| Operating Profit | 102 | 129 | 198 | -14 | -116 | -80 | -122 | -126 | -128 | -166 | -284 | -366 |
| OPM % | 20% | 24% | 32% | -5% | -917% | -593% | -1,032% | -929% | -1,094% | -2,487% | -3,999% | -4,152% |
| Other Income | 19 | 21 | 23 | 27 | 14 | 8 | 5 | 14 | 29 | 11 | 14 | 21 |
| Interest | 6 | 6 | 5 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 18 | 21 | 21 | 11 | 4 | 4 | 4 | 7 | 6 | 6 | 6 | 6 |
| Profit before tax | 98 | 123 | 196 | 0 | -106 | -77 | -122 | -118 | -106 | -161 | -276 | -352 |
| Tax % | 26% | 29% | 37% | 15,038% | -11% | -7% | 0% | 0% | -1% | 0% | 0% | |
| Net Profit | 72 | 87 | 124 | -24 | -94 | -72 | -122 | -118 | -105 | -161 | -276 | -352 |
| EPS in Rs | 3.76 | 4.57 | 6.48 | -1.25 | -4.94 | -3.78 | -5.59 | -5.42 | -4.82 | -7.37 | -10.48 | -14.44 |
| Dividend Payout % | 35% | 15% | 15% | -80% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | -35% | -12% | -19% | 17% | ||
| Compounded Profit Growth | % | % | % | -91% | ||
| Stock Price CAGR | 38% | 31% | 66% | 59% | ||
| Return on Equity | -24% | -68% | -66% | -82% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 15 | 22 | 22 | 22 | 26 |
| Reserves | 547 | 583 | 654 | 755 | 226 | 131 | 95 | 82 | 354 | 248 | 88 | 565 |
| Borrowings | 109 | 83 | 71 | 34 | 3 | 6 | 5 | 3 | 2 | 1 | 0 | 17 |
| Other Liabilities | 105 | 74 | 78 | 118 | 62 | 33 | 16 | 9 | 12 | 14 | 25 | 16 |
| Total Liabilities | 773 | 751 | 816 | 919 | 303 | 182 | 128 | 108 | 389 | 285 | 135 | 624 |
| Fixed Assets | 172 | 305 | 306 | 308 | 22 | 25 | 21 | 38 | 37 | 28 | 60 | 73 |
| CWIP | 107 | 7 | 10 | 25 | 0 | 0 | 5 | 4 | 0 | 0 | 0 | 4 |
| Investments | 0 | 0 | 301 | 279 | 223 | 0 | 0 | 45 | 46 | 76 | 22 | 181 |
| Other Assets | 494 | 439 | 199 | 308 | 58 | 157 | 103 | 22 | 305 | 181 | 53 | 367 |
| Total Assets | 773 | 751 | 816 | 919 | 303 | 182 | 128 | 108 | 389 | 285 | 135 | 624 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 143 | 68 | 109 | 70 | -53 | -135 | -96 | -128 | -116 | -115 | -155 | -300 |
| Cash from Investing Activity | -110 | -39 | -311 | -1 | 30 | 146 | 56 | -22 | -248 | 94 | 155 | -462 |
| Cash from Financing Activity | 179 | -68 | -30 | -52 | 5 | 3 | 35 | 146 | 396 | -1 | -1 | 757 |
| Net Cash Flow | 212 | -39 | -232 | 17 | -18 | 14 | -5 | -4 | 32 | -22 | -1 | -5 |
| Free Cash Flow | 25 | 10 | 79 | 28 | -92 | -137 | -102 | -147 | -119 | -113 | -193 | -305 |
| CFO/OP | 113% | 93% | 111% | 57% | 262% | 114% | 119% | 104% | 91% | 95% | 93% | 106% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 28 | 39 | 31 | 36 | 3 | 66 | 48 | 40 | 22 | 40 | 73 | 78 |
| Inventory Days | 165 | 183 | 222 | 329 | 0 | |||||||
| Days Payable | 89 | 78 | 91 | 134 | ||||||||
| Cash Conversion Cycle | 105 | 144 | 162 | 231 | 3 | 66 | 48 | 40 | 22 | 40 | 73 | 78 |
| Working Capital Days | 49 | 55 | 42 | 82 | 23 | 704 | 1,084 | 234 | 265 | 101 | -440 | 506 |
| ROCE % | 13% | 15% | 24% | -4% | -54% | -58% | -118% | -53% | -36% | -87% | -80% |
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Jul 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 69.56% | 69.56% | 70.26% | 70.26% | 70.26% | 70.26% | 70.26% | 67.36% | 67.36% | 70.15% | 70.08% | 65.47% |
| FIIs | 0.54% | 0.46% | 0.45% | 0.33% | 0.34% | 0.25% | 0.58% | 1.17% | 1.07% | 0.91% | 0.56% | 0.48% |
| DIIs | 0.01% | 1.05% | 1.05% | 1.05% | 1.05% | 0.01% | 0.03% | 3.39% | 3.39% | 4.62% | 2.93% | 2.73% |
| Public | 29.88% | 28.91% | 28.21% | 28.34% | 28.35% | 29.47% | 29.12% | 28.07% | 28.18% | 24.32% | 26.42% | 31.32% |
| No. of Shareholders | 74,003 | 68,959 | 66,116 | 63,975 | 63,537 | 64,603 | 66,159 | 64,921 | 64,381 | 63,915 | 66,791 | 66,647 |
Fundamentals
Market Cap₹ 9,176 Cr.
Current Price₹ 325
Book Value₹ 22.4
ROCE-79.5 %
ROE-81.5 %
Dividend Yield0.00 %
Face Value₹ 1.00
Compounded Sales Growth (TTM)17%
Compounded Profit Growth (TTM)-91%
Consolidated figures.
Valuation
Market capRs 8,131 Cr
Enterprise valueRs 7,810 Cr
Price to book13.75x
Price to sales921.83x
EV / sales885.46x
Earnings yield-4.33%
P/B, 3-year average12.16x
P/B, 5-year average10.44x
Profitability
Operating margin (excl. other income)-3999.30%
Operating margin (incl. other income)-3803.38%
EBITDA margin-3919.84%
Pre-tax margin-3996.03%
Net profit margin-3995.92%
Net margin, latest quarter-3574.51%
ROE-78.80%
ROCE-76.88%
ROA-72.78%
ROE, 3-year average-65.32%
ROCE, 3-year average-64.63%
ROA, 3-year average-60.17%
ROE, 5-year average-73.13%
ROCE, 5-year average-71.55%
ROA, 5-year average-66.26%
ROIC (approx.)-130.12%
Other income / net worth2.36%
Growth
Sales growth (latest year)6.76%
Sales CAGR, 3 years-19.32%
Sales CAGR, 5 years-12.01%
Sales growth QoQ134.87%
Sales growth YoY (latest quarter)90.91%
Per share
EPS (TTM)Rs -13.36
EPS (latest year)Rs -10.48
EPS (latest quarter)Rs -4.84
EPS, 3-year averageRs -7.56
EPS, 5-year averageRs -7.30
Book value per shareRs 22.42
Sales per shareRs 0.33
Cash flow per shareRs -11.37
Free cash flow per shareRs -11.57
Efficiency
Asset turnover0.01x
Fixed asset turnover0.10x
Inventory turnover21.80x
Inventory days17 days
Debtor days78 days
Debtors turnover4.71x
Creditor days134 days
Cash conversion cycle78 days
Working capital days506 days
Leverage
Total debtRs 17 Cr
Cash and bankRs 337 Cr
Net debtRs -321 Cr
Debt to equity0.03x
Interest coverage-1135.94x
Current ratio (filing 2026-03-31)17.69x
Quick ratio (filing 2026-03-31)17.69x
Trade payables (filing 2026-03-31)Rs 5 Cr
Owners' fund to total sources94.74%
Debt to assets2.67%
Cash flow
Cash from Operating Activity (latest year)Rs -300 Cr
Cash from Investing Activity (latest year)Rs -462 Cr
Cash from Financing Activity (latest year)Rs 757 Cr
Net Cash Flow (latest year)Rs -5 Cr
Free cash flow (latest year)Rs -305 Cr
Statement figures
Net sales (TTM)Rs 9 Cr
Net sales (latest year)Rs 7 Cr
Sales (latest quarter)Rs 4 Cr
Operating profit excl. other income (latest year)Rs -284 Cr
Operating profit (latest quarter)Rs -132 Cr
Other income (TTM)Rs 21 Cr
EBITDA (TTM)Rs -346 Cr
PBDT (TTM)Rs -346 Cr
Profit before tax (TTM)Rs -352 Cr
Net profit (TTM)Rs -352 Cr
Net profit (latest year)Rs -276 Cr
Net profit (latest quarter)Rs -128 Cr
Depreciation (TTM)Rs 6 Cr
Depreciation (latest quarter)Rs 2 Cr
Interest (TTM)Rs 0 Cr
Cost of goods sold (latest year)Rs 2 Cr
Total expenditure (latest year)Rs 291 Cr
Total income (latest year)Rs 21 Cr
Share capitalRs 26 Cr
ReservesRs 565 Cr
Shareholders' fundsRs 591 Cr
Total assetsRs 624 Cr
Net blockRs 73 Cr
Capital work in progressRs 4 Cr
InvestmentsRs 181 Cr
ReceivablesRs 2 Cr
InventoryRs 0 Cr
Other liabilitiesRs 16 Cr
Shares outstanding (crore)26.37
Ownership
Promoter holding65.47% (-1.89 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/B 13.75 is at the 54th percentile (median 13.00).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | SUVEN | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -8.0% | -2.8% | -5.2 pts |
| 1 month | -19.2% | -6.8% | -12.4 pts |
| 3 months | -5.9% | -7.6% | +1.7 pts |
| 6 months | +134.1% | +0.4% | +133.7 pts |
| 1 year | +40.4% | -9.9% | +50.3 pts |
| 2 years | +104.3% | -13.6% | +117.9 pts |
| 3 years | +333.9% | +14.2% | +319.7 pts |
| 5 years | +231.3% | +27.9% | +203.4 pts |
2 mutual fund schemes hold about ₹0 Cr.
Over three months 2 bought more and 0 sold (share counts, price move removed).
| Fund | Weight | Est. Cr | 3m shares |
|---|---|---|---|
| Bandhan BSE Healthcare Index Fund | 0.18% | 0 | +42% |
| Motilal Oswal BSE 1000 Index Fund | 0.01% | 0 | +49% |
Red flags
F-score 1 of 8| look | Share dilution Share count up 21% in a year, 21% in three |
| look | Repeated losses Net loss in each of the last two years |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹4 Cr +100.0% vs Jun 2025.
Net loss ₹128 Cr.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Syngene International Ltd | 14,823 | 50.0 | 9.99 % |
| Indegene Ltd | 14,580 | 35.0 | 18.8 % |
| Vimta Labs Ltd | 2,642 | 32.7 | 25.2 % |
| Fabtech Technologies Ltd | 661 | 13.6 | 13.6 % |
| Bilcare Ltd | 229 | 11.5 | 7.06 % |
| Take Ltd | 208 | 35.2 | 18.5 % |
| Novelix Pharmaceuticals Ltd | 199 | 55.1 | 10.9 % |
| Jeevan Scientific Technology Ltd | 163 | 46.7 | 5.01 % |
| Adeshwar Meditex Ltd | 24 | 19.4 | 5.21 % |
| Vanta Bioscience Ltd | 15 | 133 | 1.19 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2024-07-30 | Annual General Meeting | |
| 2023-08-02 | Annual General Meeting | |
| 2022-10-17 | Rights 1:2 @ Premium Rs 54/- | |
| 2022-07-29 | Annual General Meeting | |
| 2021-08-02 | Annual General Meeting | |
| 2020-09-11 | Annual General Meeting | |
| 2020-01-21 | Demerger | |
| 2019-08-08 | Annual General Meeting | |
| 2019-02-14 | Interim Dividend - Rs 1.50 Per Share | |
| 2018-08-09 | Annual General Meeting | |
| 2018-02-06 | Interim Dividend - Rs 1.50 Per Share (Purpose Revised) | |
| 2017-08-09 | Annual General Meeting | |
| 2017-02-08 | Interim Dividend Re 1 Per Share | |
| 2016-08-04 | Annual General Meeting | |
| 2016-03-14 | Interim Dividend - Re 1/- Per Share / Special Dividend - Re 1/- Per Share (Purpose Revised) | |
| 2015-07-23 | Annual General Meeting/Dividend - Re 0.60/- Per Share | |
| 2014-07-24 | Annual General Meeting /Final Dividend - Re 0.50/- Per Share + Special Dividend - Rs 2/- Per Share | |
| 2013-08-01 | Annual General Meeting / Dividend - Re.0.30/- Per Equity Share | |
| 2012-09-17 | Annual General Meeting And Dividend Re.0.30 Per Share | |
| 2011-08-01 | Annual General Meeting And Dividend Re.0.25 Per Share | |
| 2010-07-19 | Agm/Div-Re.0.25 Per Share | |
| 2009-09-14 | Agm/Div-Re.0.25 Per Share | |
| 2008-09-11 | Agm/Dividend - 25% | |
| 2007-09-21 | Agm/Dividend-25% | |
| 2007-03-23 | Fv Spl-Rs2 To Re1/Bon-1:1 | 0.5000 |
| 2006-09-25 | Agm/Dividend-50% |
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Close to Close price movement greater than 75perc in previous 6 monthsEPS in the scrip is zero (4 trailing quarters)High low price variation greater than 100perc in previous 6 monthsHigh low price variation greater than 200perc in previous 365 DaysLoss making
Quick answers
What is the market cap of Suven Life Sciences Ltd?
Suven Life Sciences Ltd (SUVEN) has a market capitalisation of Rs 9,176 Cr. at the 2026-10-01 close.
What were Suven Life Sciences Ltd's latest quarterly results?
In the Jun 2026 quarter, Suven Life Sciences Ltd sales was Rs 4 Cr (+100.0% vs Jun 2025) with a net loss of Rs 128 Cr.
What is the 52-week high and low of Suven Life Sciences Ltd?
The 52-week high is Rs 403.35 and the 52-week low is Rs 124.11.